Aduro Biotech Inc said its pancreatic cancer drug did not improve overall survival in patients who did not show improvement after at least two prior therapies, in a mid-stage study.
Biogen has made several bold steps to further its work in gene therapy. The company announced a collaboration with two gene therapy experts from the University of Pennsylvania, as well as a gene therapy technology licensing deal with Maryland-based RegenxBio.
Pfizer is acquiring Palo Alto, California-based Anacor Pharmaceuticals for $5.2 billion.
King of Prussia, Pennsylvania-based Trevena plans to shift its focus after its TRV027 flopped in a Phase IIb clinical trial for acute heart failure.
Pfizer Inc. has taken steps to ensure that none of its products are used in lethal injections, the largest U.S. drugmaker said.
Roche’s Jennifer Cook is the Healthcare Businesswomen’s Association’s 2016 WOTY.
Merck KGaA expects to continue delivering market-beating sales growth, helped in part by new gene modification techniques.
Drugs targeting DNA repair mechanisms inside cells are showing real promise for a range of tumors.
Mylan N.V. announced an agreement to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings LLC for $950 million in cash at closing.
Sanofi is not one to take no for an answer. Deal hungry Sanofi is carrying out its threats for a hostile takeover of Bay Area’s Medivation. Despite repeated rejections by that company’s board of directors on a possible merger, Sanofi said it plans to nominate eight directors to replace Medivation’s current board and has also filed pre-merger notifications with the Federal Trade Commission.